Sundar PichaiSundar Pichai earned $164M in 2023

Andres Ruiz Briseno is the Senior Vice President and Principal Accounting Officer of IDEAYA Biosciences, Inc., having joined them in 2021 and rising quickly through the ranks. At just 38 years old, he brings over a decade of finance experience,...

Quick Links
I

Andres Ruiz Briseno

CEO of IDEAYA Biosciences, Inc.

Sector of Economy

Healthcare

CEO of IDEAYA Biosciences, Inc. for

1 year 11 months (Jul 2023 - Present)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Andres Ruiz Briseno

Holdings

See how much did Andres Ruiz Briseno make over time.

As of the end of 2023, Andres holds options totaling 65,000 shares in IDEAYA Biosciences, including 22,500 options granted in June 2023 due to his promotion. His holdings give him a substantial stake in the company's future. His options were...

Mar 18, 2025

Total Stock Sold

$384.18K

IDYA

$384.18K

10,000 IDYA shares

What if they kept their stock?

If Andres Ruiz Briseno didn't sell their stock, today they would have:
Extra IDYA10,000 shares worth $74.50K.
This is -80.61% and $309.68K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Andres Ruiz Briseno.

IDYA

$92.04K

IDYA at $46.02/share

Feb 9, 2024

Sale

IDYA

$84.05K

IDYA at $42.03/share

Jan 22, 2024

Sale

IDYA

$76.03K

IDYA at $38.01/share

Jan 12, 2024

Sale

IDYA

$68.01K

IDYA at $34.00/share

Dec 14, 2023

Sale

IDYA

$60.02K

IDYA at $30.01/share

Sep 1, 2023

Sale

Compensation History

See how much did Andres Ruiz Briseno make over time.

In 2023, Andres Ruiz Briseno's total compensation reflected his essential role at IDEAYA Biosciences, totaling $492,625. This includes a base salary of $357,500, a performance-based bonus of $125,125, and additional benefits valued at $15,000. His bonus was contingent on achieving specific corporate objectives and individual assessments, indicating the performance-driven nature of his role. The compensation structure is designed to ensure alignment with corporate goals, which is critical in the life sciences sector. His recent promotion to Senior Vice President shows a clear upward trajectory in his career, which is likely to influence future compensation adjustments as the company grows. The company’s approach to executive compensation is competitive, aiming to attract and retain talent capable of navigating the complexities of the biotech field.

Year

2023

Total Compensation

$497.63K

Salary

$357.50K

Board Justification

The compensation program is designed to encourage management to achieve corporate objectives while managing business risks, providing a competitive total compensation package through base salary, performance-based bonuses, and long-term equity incentives.

Bonus

$125.13K

Board Justification

The annual performance-based cash bonus earned based on the achievement of corporate performance objectives and individual performance assessment for the fiscal year ended December 31, 2023.

Other

$15.00K

Board Justification

Includes a $150 monthly cell phone allowance and 401(k) employer matching contributions.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards were vested in 2023.

Performance Metrics

The performance metrics for the CEO's compensation in 2023 were based on corporate performance objectives related to clinical development and individual performance assessments.